Karolina Akinosoglou, Konstantinos Leventogiannis, Elisavet Tasouli, Nikolaos Kakavoulis, Georgios Niotis, Sarantia Doulou, Lamprini Skorda, Konstantina Iliopoulou, Anna Papailiou, Paraskevi Katsaounou, Vassiliki Rapti, George Chrysos, Theodoros Seferlis, Styliani Gerakari, Konstantina Dakou, Ilias C. Papanikolaou, Haralampos Milionis, Samantha Kewitz, Sara Georgiadou, Theano Kontopoulou, Vasiliki Tzavara, Antonio Torres, Michael S. Niederman, Evangelos J. Giamarellos-Bourboulis
Int J Antimicrob Agents. 2024 Dec 6;65(2):107406
DOI: 10.1016/j.ijantimicag.2024.107406Download pdf 🡇
Funding
The ACCESS trial was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) and financially supported by Abbot Products Operations (Abbott). HISS oversaw the study design, implementation, data analysis, interpretation, and determination regarding publication. The funding source, Abbott, did not take part in the design, execution, analysis, or interpretation of the study, nor did it influence the decision to publish. Publication administration was facilitated by Hughes associates, Oxford, UK.
Keywords: Pneumonia; Clarithromycin; Early response; Inflammation